Stefan F Zappe

Address:

3945 Forbes Ave, Pittsburgh, PA 15213

Phone:

412 268-0000

VIN:

KMHDH4AE4CU275245

Make:

HYUNDAI

Model:

ELANTRA

Year:

2012

US Patent:

20180252734, Sep 6, 2018

Filed:

Mar 1, 2018

Appl. No.:

15/909677

Inventors:

- Danbury CT, US
Bryan Laulicht - Danbury CT, US
Stefan Zappe - Danbury CT, US
Solomon Steiner - Mount Kisco NY, US

International Classification:

G01N 33/86
B01L 3/00
B01L 9/00
G01N 33/49

Abstract:

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

US Patent:

20160069913, Mar 10, 2016

Filed:

Sep 9, 2015

Appl. No.:

14/849348

Inventors:

- Danbury CT, US
Bryan Laulicht - Danbury CT, US
Stefan Zappe - Danbury CT, US
Solomon Steiner - Mount Kisco NY, US

International Classification:

G01N 33/86

Abstract:

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.